E-LIB Suche - Ergebnisse für: Dumonceaux, J.

1

VP.61 An AAV-shRNA DUX4-based therapy to treat facioscapulo..:

Mariot, V. ; Sidlauskaite, E. ; Gall, L. Le..
Neuromuscular Disorders. 32 (2022) - p. S107 , 2022

Link: https://doi.org/10.1016/..

2

FP.11 Impact of disease-modifying therapies on myostatin le..:

Mackels, L. ; Mariot, V. ; Servais, L..
Neuromuscular Disorders. 32 (2022) - p. S58 , 2022

Link: https://doi.org/10.1016/..

3

1st FSHD European Trial Network workshop:Working towards tr..:

Voermans, N.C. ; Vriens-Munoz Bravo, M. ; Padberg, G.W....
Neuromuscular Disorders. 31 (2021) 9 - p. 907-918 , 2021

Link: https://doi.org/10.1016/..

4

NEW THERAPEUTIC APPROACHES AND THEIR READOUT:

Dumonceaux, J. ; Mariot, V. ; Le Guiner, C....
Neuromuscular Disorders. 28 (2018) - p. S91 , 2018

Link: https://doi.org/10.1016/..

5

NEW INSIGHTS INTO CELLULAR FUNCTIONS:

Gall, I. Le ; Lucas, O. ; Roquevière, S....
Neuromuscular Disorders. 28 (2018) - p. S89 , 2018

Link: https://doi.org/10.1016/..

6

Myostatin is a reliable biomarker for monitoring drug respo..:

Mariot, V. ; Le Guiner, C. ; Inès, B....
Neuromuscular Disorders. 28 (2018) - p. S19 , 2018

Link: https://doi.org/10.1016/..

7

Myostatin expression in neuromuscular diseases:

Mariot, V. ; Le Guiner, C. ; Inès, B....
Neuromuscular Disorders. 28 (2018) - p. S2 , 2018

Link: https://doi.org/10.1016/..

8

Reversible endogenous downregulation of myostatin pathway i..:

Mariot, V. ; Joubert, R. ; Hourdé, C....
Neuromuscular Disorders. 27 (2017) - p. S97-S98 , 2017

Link: https://doi.org/10.1016/..

9

Myostatin expression levels in neuromuscular diseases parti..:

Mariot, V. ; Joubert, R. ; Hourdé, C....
Neuromuscular Disorders. 27 (2017) - p. S231 , 2017

Link: https://doi.org/10.1016/..

10

Myostatin inhibition for neuromuscular disorders: defining ..:

Mariot, V. ; Joubert, R. ; Hourdé, C....
Neuromuscular Disorders. 27 (2017) - p. S8 , 2017

Link: https://doi.org/10.1016/..

11

Correlation between low FAT1 expression and early affected ..:

Mariot, V. ; Roche, S. ; Hourdé, C....
Neuromuscular Disorders. 25 (2015) - p. S312 , 2015

Link: https://doi.org/10.1016/..

12

P.16.3 DUX4 and DUX4 downstream target genes are expressed ..:

Ferreboeuf, M. ; Mariot, V. ; Bessières, B....
Neuromuscular Disorders. 23 (2013) 9-10 - p. 823 , 2013

Link: https://doi.org/10.1016/..

13

G.P.15.12 Dux4 over-expression in normal mouse: Generation ..:

Dumonceaux, J. ; Marie, S. ; Ferry, A....
Neuromuscular Disorders. 19 (2009) 8-9 - p. 650-651 , 2009

Link: https://doi.org/10.1016/..

14

G.P.8.07 Increased oxidative metabolism in mdx muscle treat..:

Hourdé, C. ; Marie, S. ; Mouisel, E....
Neuromuscular Disorders. 18 (2008) 9-10 - p. 783-784 , 2008

Link: https://doi.org/10.1016/..

15

G.P.7.08 FRG1 over-expression induces severe dystrophic phe..:

Dumonceaux, J. ; Berger, C. ; Marie, S..
Neuromuscular Disorders. 17 (2007) 9-10 - p. 808 , 2007

Link: https://doi.org/10.1016/..